Narcolepsy type 1

Alkermes Advances Narcolepsy Therapy with Promising Phase 2 Trial Results for Alixorexton

4 days ago talkbio0Tagged alixorexton, Alkermes, Cataplexy, Daytime Somnolence, Excessive (qualifier value), late-stage testing, Narcolepsy, Narcolepsy type 1, normative wakefulness, Orexin Receptor Agonist, Vibrance-1 study

Alkermes; narcolepsy; alixorexton; Phase 2 trial; orexin 2 receptor agonist; narcolepsy type 1; normative wakefulness; late-stage testing; Vibrance-1 study; cataplexy; excessive daytime sleepiness

Takeda’s Oveporexton Succeeds in Two Phase III Trials, Paving Way for Narcolepsy Drug Filings

2 weeks ago talkbio0Tagged Clinical Trials, File (record), Narcolepsy, Narcolepsy type 1, orexin agonist, oveporexton, Phase 3 Clinical Trials, Takeda, United States Food and Drug Administration

Takeda; Oveporexton; narcolepsy; Phase III trials; orexin agonist; FDA filing; Narcolepsy Type 1; clinical trial results

Takeda’s Orexin Narcolepsy Drug TAK-861 Poised for Phase III Trials After Promising Results

1 year ago talkbio0Tagged Agonist, Narcolepsy, Narcolepsy type 1, Phase 3 Clinical Trials, TAK-861, Takeda

Takeda, TAK-861, narcolepsy, orexin receptor 2 agonist, Phase III trials, narcolepsy type 1, sleep disorders